Lichtenstein, G. R., Rogler, G., Ciorba, M. A., Su, C., Chan, G., Pedersen, R. D., . . . Panés, J. (2020). Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis.
Trích dẫn kiểu ChicagoLichtenstein, Gary R., et al. "Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program." Inflamm Bowel Dis 2020.
Trích dẫn MLALichtenstein, Gary R., et al. "Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program." Inflamm Bowel Dis 2020.